Disease · EFO_0007624
suicide
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. suicide. Diseases, record EFO_0007624. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0007624
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- suicide
- Open Targets ID
- EFO_0007624
- Highest stage of its drugs
- Phase 3, for 4 of its 10 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| KETAMINE | CHEMBL742 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 7 | Drugs and targets |
| BUPRENORPHINE | CHEMBL511142 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BUPRENORPHINE HYDROCHLORIDE | CHEMBL2368861 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RISPERIDONE | CHEMBL85 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MIDAZOLAM | CHEMBL655 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| KETAMINE HYDROCHLORIDE | CHEMBL1714 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITROUS OXIDE | CHEMBL1234579 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PSILOCYBIN | CHEMBL194378 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets29
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 1 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2905 | Drugs and targets |
| GRIN2D | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2906 | Drugs and targets |
| GRIN3A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/116443 | Drugs and targets |
| GRIN3B | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/116444 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 2 | Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 2 | Kappa opioid receptor agonist | Phase 3 | https://conductscience.org/library/genes/4986 | Drugs and targets |
1 to 10 of 29
See all 29 targetsTrials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03395314 | Ketamine in Borderline Personality Disorder | Phase 2 | 22 | 2023-06-26 | Borderline Personality Disorder | KETAMINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04260607 | Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department | Phase 3 | 1 | 2024-11-19 | Suicide, Suicide Threat, Depression Severe | KETAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT06222268 | Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery | Phase 1/2 | 280 | PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use | CANNABIDIOL, DRONABINOL | Its record names the disease | ClinicalTrials.gov | |
| NCT06698848 | Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome | Phase 1 | 120 | Depression, Suicide | KETAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07569198 | Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | Phase 2 | 120 | Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder, Treatment-resistant Bipolar Depression, Major Depressive Disorder (MDD), Bipolar Disorder (BD), Bipolar Disorder I or II, Suicidal Ideation | KETAMINE, MIDAZOLAM | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06636357 | Nitrous Oxide in the Treatment of Acute Suicidal Ideation | Phase 2 | 85 | Suicidality, EEG, Suicidal Ideation, Nitrous Oxide, Biomarkers / Blood, Biomarkers / Hair | NITROUS OXIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06480500 | i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial | Phase 2 | 76 | Major Depressive Disorder, Suicide, Treatment Resistant Depression | KETAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01046851 | A Study of Nopan Treatment of Acute Suicidality | Phase 3 | 60 | Suicidality | BUPRENORPHINE HYDROCHLORIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04763343 | Ketamine Treatment of Youth Suicide Attempters | Phase 3 | 60 | Suicide, Attempted | KETAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04592809 | Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents | Phase 3 | 50 | Suicide, Attempted, Suicide and Depression, Suicide Threat | KETAMINE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Midazolam vs Low Dose Ketamine: Change in Adverse Events | 0 of 12 | 0 of 10 | 22 | NCT03395314 | Trial comparisons |
| Midazolam vs Low Dose Ketamine: deaths from any cause | 0 of 12 | 0 of 10 | 22 | NCT03395314 | Trial comparisons |
| Midazolam vs Low Dose Ketamine: serious adverse events | 0 of 12 | 0 of 10 | 22 | NCT03395314 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0007624
GET https://conductscience.org/api/diseases/v1/EFO_0007624/targets?page=2